Replication study of plasma proteins relating to Alzheimer's pathology.
ATN framework
Alzheimer's disease
biomarker
dementia
network analysis
plasma proteomics
replication
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
26
11
2020
received:
24
07
2020
accepted:
05
02
2021
pubmed:
2
4
2021
medline:
31
12
2021
entrez:
1
4
2021
Statut:
ppublish
Résumé
This study sought to discover and replicate plasma proteomic biomarkers relating to Alzheimer's disease (AD) including both the "ATN" (amyloid/tau/neurodegeneration) diagnostic framework and clinical diagnosis. Plasma proteins from 972 subjects (372 controls, 409 mild cognitive impairment [MCI], and 191 AD) were measured using both SOMAscan and targeted assays, including 4001 and 25 proteins, respectively. Protein co-expression network analysis of SOMAscan data revealed the relation between proteins and "N" varied across different neurodegeneration markers, indicating that the ATN variants are not interchangeable. Using hub proteins, age, and apolipoprotein E ε4 genotype discriminated AD from controls with an area under the curve (AUC) of 0.81 and MCI convertors from non-convertors with an AUC of 0.74. Targeted assays replicated the relation of four proteins with the ATN framework and clinical diagnosis. Our study suggests that blood proteins can predict the presence of AD pathology as measured in the ATN framework as well as clinical diagnosis.
Substances chimiques
Amyloid beta-Peptides
0
Apolipoprotein E4
0
Biomarkers
0
Blood Proteins
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1452-1464Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2021 the Alzheimer's Association.
Références
Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018;25:59-70.
Schöll M, Maass A, Mattsson N, et al. Biomarkers for tau pathology. Mol Cell Neurosci. 2019;97:18-33.
Cohen AD, Landau SM, Snitz BE, Klunk WE, Blennow K, Zetterberg H. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Mol Cell Neurosci. 2018;97:3-17.
Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535-562.
Zetterberg H, Skillback T, Mattsson N, et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol. 2016;73:60-67.
Portelius E, Zetterberg H, Skillback T, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain. 2015;138:3373-3385.
Lista S, Faltraco F, Prvulovic D, Hampel H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol. 2013;101-102:1-17.
de Almeida SM, Shumaker SD, LeBlanc SK, et al. Incidence of post-dural puncture headache in research volunteers. Headache. 2011;51:1503-1510.
Hye A, Lynham S, Thambisetty M, et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006;129:3042-3050.
Thambisetty M, Simmons A, Velayudhan L, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010;67:739-748.
Kiddle SJ, Sattlecker M, Proitsi P, et al. Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis. 2014;38:515-531.
Sattlecker M, Kiddle SJ, Newhouse S, et al. Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement. 2014;10:724-734.
Baird AL, Westwood S, Lovestone S. Blood-based proteomic biomarkers of Alzheimer's disease pathology. Front Neurol. 2015;6:236.
Shi L, Westwood S, Baird AL, et al. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's Dement. 2019;15:1478-1488.
Westwood S, Baird AL, Anand SN, et al. Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort. J Alzheimer's Dis. 2020:1-13.
Bos I, Vos S, Vandenberghe R, et al. The EMIF-AD multimodal biomarker discovery study: design, methods and cohort characteristics. Alzheimers Res Ther. 2018;10:64.
Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 2010;5:e15004.
Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008;9:559.
Lista S, Zetterberg H, O'Bryant SE, Blennow K, Hampel H. Evolving relevance of neuroproteomics in Alzheimer's disease. Neuroproteomics. Springer; 2017:101-115.
Castrillo JI, Lista S, Hampel H, Ritchie CW. Systems biology methods for Alzheimer's disease research toward molecular signatures, subtypes, and stages and precision medicine: application in cohort studies and trials. Biomarkers Alzheimer's Dis. Drug Dev.. Springer; 2018:31-66.
Kirouac L, Rajic AJ, Cribbs DH, Padmanabhan J. Activation of Ras-ERK signaling and GSK-3 by amyloid precursor protein and amyloid beta facilitates neurodegeneration in Alzheimer's disease. ENeuro. 2017;4.
Ogishima S, Mizuno S, Kikuchi M, et al. A map of Alzheimer's disease-signaling pathways: a hope for drug target discovery. Clin Pharmacol Ther. 2013;93:399-401.
Nevado-Holgado AJ, Ribe E, Thei L, et al. Genetic and real-world clinical data, combined with empirical validation, nominate jak-stat signaling as a target for Alzheimer's disease therapeutic development. Cells. 2019;8:425.
Mattsson-Carlgren N, Leuzy A, Janelidze S, et al. The implications of different approaches to define AT (N) in Alzheimer disease. Neurology. 2020;94(21):e2233-e2244.
Kalman J, McConathy W, Araoz C, Kasa P, Lacko AG. Apolipoprotein D in the aging brain and in Alzheimer's dementia. Neurol Res. 2000;22:330-336.
Ishii M. Apolipoprotein B as a new link between cholesterol and Alzheimer disease. JAMA Neurol. 2019;76:751-753.
Crehan H, Hardy J, Pocock J. Microglia, Alzheimer's disease, and complement. Int J Alzheimer's Dis. 2012;2012:983640.
Shen Y, Yang L, Li R. What does complement do in Alzheimer's disease? Old molecules with new insights. Transl Neurodegener. 2013;2:1-11.
Zamolodchikov D, Chen Z-L, Conti BA, Renné T, Strickland S. Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma. Proc Natl Acad Sci U S A. 2015;112:4068-4073.
Goldhardt O, Warnhoff I, Yakushev I, et al. Kallikrein-related peptidases 6 and 10 are elevated in cerebrospinal fluid of patients with Alzheimer's disease and associated with CSF-TAU and FDG-PET. Transl Neurodegener. 2019;8:1-13.
Cardoso SM, Proença MT, Santos S, Santana I, Oliveira CR. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging. 2004;25:105-110.
Goldberg J, Currais A, Prior M, et al. The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell. 2018;17:e12715.
Singh PP, Singh M, Mastana SS. APOE distribution in world populations with new data from India and the UK. Ann Hum Biol. 2006;33:279-308.
Shi L, Baird AL, Westwood S, et al. A decade of blood biomarkers for Alzheimer's disease research: an evolving field, improving study designs, and the challenge of replication. J Alzheimers Dis. 2018;62:1181-1198.
Fujita T, Matsushita M, Endo Y. The lectin-complement pathway-its role in innate immunity and evolution. Immunol Rev. 2004;198:185-202.
Lanzrein A-S, Jobst KA, Thiel S, et al. Mannan-binding lectin in human serum, cerebrospinal fluid and brain tissue and its role in Alzheimer's disease. Neuroreport. 1998;9:1491-1495.
Liu RM, van Groen T, Katre A, et al. Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease. Neurobiol Aging. 2011;32:1079-1089.
Akhter H, Huang WT, van Groen T, Kuo HC, Miyata T, Liu RM. A small molecule inhibitor of plasminogen activator inhibitor-1 reduces brain amyloid-β load and improves memory in an animal model of Alzheimer's disease. J Alzheimers Dis. 2018;64:447-457.
Ozawa D, Nomura R, Mangione PP, et al. Multifaceted anti-amyloidogenic and pro-amyloidogenic effects of C-reactive protein and serum amyloid P component in vitro. Sci Rep. 2016;6:29077.
Wennström M, Nielsen HM. Cell adhesion molecules in Alzheimer's disease. Degener Neurol Neuromuscul Dis. 2012;2:65-77.